GoAI
Get started
Dingdang Health Technology Group Ltd. logo

Dingdang Health Technology Group Ltd.

9886.HK

HKSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Latest quote

HK$0.73

−HK$0.05 · -6.41%

Aug 24, 10:10 AM HKT

9886.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
CN
CEO
Wenlong Yang
Listed since
Sep 14, 2022
Employees
2,232

Market position

52-week range

Current HK$0.73

Open
HK$0.73
Previous close
HK$0.78
Volume
35.5K
0.04× average
Average volume
823.7K
Average daily volume
Market cap
904.71M HKD
Beta
0.95
Market reference 1
50-day average
HK$0.8611
-15.22% below average
200-day average
HK$0.9452
-22.77% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.07B CNY
P/E (TTM)
-16.55×
P/B (TTM)
0.49×
P/S (TTM)
0.16×
EV / EBITDA
-67.8×
Earnings yield
-3.93%
Free cash flow yield
9.82%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.26%
Operating margin
-1.09%
Net margin
-1.00%
Return on equity
-2.95%
Return on assets
-1.73%
Return on invested capital
-2.71%

Financial health

Debt / equity
0.17×
Current ratio
2.28×
Altman Z-score
-0.6
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends49%8%-34%-76%Gross margin, FY2021: 33.65%Gross margin, FY2022: 38.94%Gross margin, FY2023: 31.10%Gross margin, FY2024: 32.95%Gross margin, FY2025: 35.26%Operating margin, FY2021: -17.96%Operating margin, FY2022: -7.54%Operating margin, FY2023: -5.73%Operating margin, FY2024: -4.61%Operating margin, FY2025: -1.09%Net margin, FY2021: -42.90%Net margin, FY2022: -65.45%Net margin, FY2023: -4.65%Net margin, FY2024: -8.06%Net margin, FY2025: -1.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 33.65%. Gross margin FY2022 38.94%. Gross margin FY2023 31.10%. Gross margin FY2024 32.95%. Gross margin FY2025 35.26%. Operating margin FY2021 -17.96%. Operating margin FY2022 -7.54%. Operating margin FY2023 -5.73%. Operating margin FY2024 -4.61%. Operating margin FY2025 -1.09%. Net margin FY2021 -42.90%. Net margin FY2022 -65.45%. Net margin FY2023 -4.65%. Net margin FY2024 -8.06%. Net margin FY2025 -1.00%.

Income trends

Revenue

4.89B CNY+4.68%

Operating income

−53.44M CNY+75.16%

Net income

−49.02M CNY+86.98%
Income trends across reported periods5.66B CNY2.57B CNY−517.04M CNY−3.61B CNYRevenue, FY2021: 3.68B CNYRevenue, FY2022: 4.33B CNYRevenue, FY2023: 4.86B CNYRevenue, FY2024: 4.67B CNYRevenue, FY2025: 4.89B CNYOperating income, FY2021: −660.65M CNYOperating income, FY2022: −326.42M CNYOperating income, FY2023: −278.25M CNYOperating income, FY2024: −215.18M CNYOperating income, FY2025: −53.44M CNYNet income, FY2021: −1.58B CNYNet income, FY2022: −2.83B CNYNet income, FY2023: −225.81M CNYNet income, FY2024: −376.5M CNYNet income, FY2025: −49.02M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.68B CNY. Revenue FY2022 4.33B CNY. Revenue FY2023 4.86B CNY. Revenue FY2024 4.67B CNY. Revenue FY2025 4.89B CNY. Operating income FY2021 −660.65M CNY. Operating income FY2022 −326.42M CNY. Operating income FY2023 −278.25M CNY. Operating income FY2024 −215.18M CNY. Operating income FY2025 −53.44M CNY. Net income FY2021 −1.58B CNY. Net income FY2022 −2.83B CNY. Net income FY2023 −225.81M CNY. Net income FY2024 −376.5M CNY. Net income FY2025 −49.02M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue4.89B CNY4.67B CNY4.86B CNY4.33B CNY3.68B CNY
Cost of goods sold3.16B CNY3.13B CNY3.35B CNY3.35B CNY3.2B CNY
Gross profit1.72B CNY1.54B CNY1.51B CNY1.69B CNY1.24B CNY
Research and development54.37M CNY61.19M CNY64.98M CNY88.95M CNY96.16M CNY
Selling, general, and administrative1.27B CNY1.24B CNY1.23B CNY1.24B CNY1.32B CNY
Operating expenses1.78B CNY1.75B CNY1.79B CNY1.77B CNY1.82B CNY
Interest income27.86M CNY28.73M CNY32.63M CNY17.15M CNY4.17M CNY
Interest expense12.38M CNY8.89M CNY7.88M CNY7.92M CNY17.78M CNY
Depreciation and amortization37.62M CNY53.58M CNY140M CNY45.55M CNY47.02M CNY
Operating income−53.44M CNY−215.18M CNY−278.25M CNY−326.42M CNY−660.65M CNY
Net income−49.02M CNY−376.5M CNY−225.81M CNY−2.83B CNY−1.58B CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.06

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.02-0.05-0.09-0.13Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q3 '26
Q3 2023, reported Aug 25, 2023: actual -0.086, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual -0.035, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 16, 2024: actual -0.037, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 21, 2025: actual -0.021, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 22, 2025: actual -0.044, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 21, 2026: actual -0.058, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates3B2.37B1.74B1.11BQ3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q3 '26
Q3 2023, reported Aug 25, 2023: actual 2.43B HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 2.87B HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 16, 2024: actual 2.44B HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 21, 2025: actual 1.24B HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 22, 2025: actual 2.55B HKD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 21, 2026: actual 2.78B HKD, estimate —, surprise —, Comparison unavailable.

9886.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

ETFs holding 9886.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis Emerging Markets Small Cap Equity ETF logoAvantis Emerging Markets Small Cap Equity ETFAVEE
Market value
1.22K
Weight
—
AUM
122.3M USD
Expense ratio
0.42%
Price / 1D
$68.1949+0.35%

Continue in GoAI

Research 9886.HK

research.disclaimer